 |
인쇄하기
취소
|
KFDA approves Leukemia drug, Gleevec.
The KFDA announced on June 20 that Novartis' Gleevec (imtainib mesylate), a leukemia drug, was approved to sell in Korea on June 14 as an orphan drug with precondition of its clinical phase III study for the treatment of chronic myelogenous leukemia.
The Central Pharmaceutical Affairs Review Council concluded to appoint it as an orphan drug on May 31.
Gleevec works by blocking an abnor...
The Central Pharmaceutical Affairs Review Council concluded to appoint it as an orphan drug on May 31.
Gleevec works by blocking an abnor...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.